Tumor necrosis factor-alpha promotes survival in methotrexate-exposed macrophages by an NF-kappaB-dependent pathway

Arthritis Research and Therapy

Volumn 13, Issue 1, 2011, Pages

  Lo, Susan Z Y ^a   Steer, James H ^a   Joyce, David A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; 7 AMINODACTINOMYCIN; CASPASE 3; COLONY STIMULATING FACTOR 1; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; PARTHENOLIDE; TUMOR NECROSIS FACTOR ALPHA; IMMUNOSUPPRESSIVE AGENT;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; CELL LINE; CELL SEPARATION; DRUG EFFECT; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; METABOLISM; PHYSIOLOGY; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE; CELL SEPARATION; CELL SURVIVAL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLOW CYTOMETRY; IMMUNOSUPPRESSIVE AGENTS; MACROPHAGES; METHOTREXATE; MICE; NF-KAPPA B; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79851513093     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3248     Document Type: Article

References (48)

1. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005, 5:953-964. 10.1038/nri1733, 16322748.
2. Kuhlmann T, Bitsch A, Stadelmann C, Siebert H, Bruck W. Macrophages are eliminated from the injured peripheral nerve via local apoptosis and circulation to regional lymph nodes and the spleen. J Neurosci 2001, 21:3401-3408.
3. Smith MD, Weedon H, Papangelis V, Walker J, Roberts-Thomson PJ, Ahern MJ. Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment. Rheumatology (Oxford) 2010, 49:862-875. 10.1093/rheumatology/kep467, 20147446.
4. Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, Klareskog L, Ulfgren AK. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005, 52:61-72. 10.1002/art.20764, 15641091.
5. Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003, 48:2155-2162. 10.1002/art.11098, 12905468.
6. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001, 121:1145-1157. 10.1053/gast.2001.28702, 11677207.
7. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, Feldmann M, Maini RN. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:38-47. 10.1002/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L, 10643698.
8. Gehr G, Gentz R, Brockhaus M, Loetscher H, Lesslauer W. Both tumor necrosis factor receptor types mediate proliferative signals in human mononuclear cell activation. J Immunol 1992, 149:911-917.
9. Yuan J. Transducing signals of life and death. Curr Opin Cell Biol 1997, 9:247-251. 10.1016/S0955-0674(97)80069-5, 9069264.
10. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996, 274:782-784. 10.1126/science.274.5288.782, 8864118.
11. Pennington KN, Taylor JA, Bren GD, Paya CV. IkappaB kinase-dependent chronic activation of NF-kappaB is necessary for p21(WAF1/Cip1) inhibition of differentiation-induced apoptosis of monocytes. Mol Cell Biol 2001, 21:1930-1941. 10.1128/MCB.21.6.1930-1941.2001, 86780, 11238929.
12. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 1995, 38:1762-1770. 10.1002/art.1780381209, 8849348.
13. Herman S, Zurgil N, Deutsch M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res 2005, 54:273-280. 10.1007/s00011-005-1355-8, 16134056.
14. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48:35-45. 10.1002/art.10697, 12528101.
15. Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:249-255. 10.1093/rheumatology/kem279, 18045808.
16. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004, 25:33-39. 10.1016/j.it.2003.11.003, 14698282.
17. Koizumi S, Curt GA, Fine RL, Griffin JD, Chabner BA. Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. J Clin Invest 1985, 75:1008-1014. 10.1172/JCI111761, 423648, 2579975.
18. Xu J, Tan JW, Huang L, Gao XH, Laird R, Liu D, Wysocki S, Zheng MH. Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand. J Bone Miner Res 2000, 15:2178-2186. 10.1359/jbmr.2000.15.11.2178, 11092398.
19. Yip KH, Zheng MH, Feng HT, Steer JH, Joyce DA, Xu J. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity. J Bone Miner Res 2004, 19:1905-1916. 10.1359/JBMR.040919, 15476591.
20. Yip KH, Zheng MH, Steer JH, Giardina TM, Han R, Lo SZ, Bakker AJ, Cassady AI, Joyce DA, Xu J. Thapsigargin modulates osteoclastogenesis through the regulation of RANKL-induced signaling pathways and reactive oxygen species production. J Bone Miner Res 2005, 20:1462-1471. 10.1359/JBMR.050324, 16007343.
21. Steer JH, Kroeger KM, Abraham LJ, Joyce DA. Glucocorticoids suppress tumor necrosis factor-alpha expression by human monocytic THP-1 cells by suppressing transactivation through adjacent NF-kappa B and c-Jun-activating transcription factor-2 binding sites in the promoter. J Biol Chem 2000, 275:18432-18440. 10.1074/jbc.M906304199, 10748079.
22. Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum 2008, 58:2257-2267. 10.1002/art.23667, 18668547.
23. Bruce-Gregorios JH, Soucy D, Chen MG, Benson N. Effect of methotrexate on cell cycle and DNA synthesis of astrocytes in primary culture: flow cytometric studies. J Neuropathol Exp Neurol 1991, 50:63-72. 10.1097/00005072-199101000-00005, 1985154.
24. Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997, 36:86-90. 10.1093/rheumatology/36.1.86, 9117183.
25. Raschke WC, Baird S, Ralph P, Nakoinz I. Functional macrophage cell lines transformed by Abelson leukemia virus. Cell 1978, 15:261-267. 10.1016/0092-8674(78)90101-0, 212198.
26. Pagliari LJ, Perlman H, Liu H, Pope RM. Macrophages Require Constitutive NF-kappa B Activation To Maintain A1 Expression and Mitochondrial Homeostasis. Mol Cell Biol 2000, 20:8855-8865. 10.1128/MCB.20.23.8855-8865.2000, 116114, 11073986.
27. Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 1991, 285:199-212. 10.1016/0014-5793(91)80803-B, 1649771.
28. Natoli G, Costanzo A, Guido F, Moretti F, Bernardo A, Burgio VL, Agresti C, Levrero M. Nuclear factor kB-independent cytoprotective pathways originating at tumor necrosis factor receptor-associated factor 2. J Biol Chem 1998, 273:31262-31272. 10.1074/jbc.273.47.31262, 9813034.
29. Pincheira R, Castro AF, Ozes ON, Idumalla PS, Donner DB. Type 1 TNF receptor forms a complex with and uses Jak2 and c-Src to selectively engage signaling pathways that regulate transcription factor activity. J Immunol 2008, 181:1288-1298.
30. Place RF, Haspeslagh D, Giardina C. Induced stabilization of IkappaBalpha can facilitate its re-synthesis and prevent sequential degradation. J Cell Physiol 2003, 195:470-478. 10.1002/jcp.10262, 12704657.
31. Nasu K, Nishida M, Ueda T, Yuge A, Takai N, Narahara H. Application of the nuclear factor-kappaB inhibitor BAY 11-7085 for the treatment of endometriosis: an in vitro study. Am J Physiol Endocrinol Metab 2007, 293:E16-23. 10.1152/ajpendo.00135.2006, 16896168.
32. Egberts JH, Cloosters V, Noack A, Schniewind B, Thon L, Klose S, Kettler B, von Forstner C, Kneitz C, Tepel J, Adam D, Wajant H, Kalthoff H, Trauzold A. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2008, 68:1443-1450. 10.1158/0008-5472.CAN-07-5704, 18316608.
33. Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:1068-1076. 10.1093/rheumatology/kel045, 16490750.
34. Ang ES, Pavlos NJ, Chai LY, Qi M, Cheng TS, Steer JH, Joyce DA, Zheng MH, Xu J. Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity. J Cell Physiol 2009, 221:642-649. 10.1002/jcp.21898, 19681045.
35. Majumdar S, Aggarwal BB. Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol 2001, 167:2911-2920.
36. Nakshatri H, Goulet RJ. NF-kappaB and breast cancer. Curr Probl Cancer 2002, 26:282-309. 10.1067/mcn.2002.129977, 12429950.
37. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440. 10.1146/annurev.immunol.14.1.397, 8717520.
38. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, Takahashi K, Furuya T, Ishiyama S, Kim KJ, Saito S, Nishikawa T, Takahashi N, Togari A, Tomatsu T, Suda T, Kamatani N. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001, 44:1003-1012. 10.1002/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2-#, 11352231.
39. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007, 40:251-264. 10.1016/j.bone.2006.09.023, 17098490.
40. Ikeda F, Matsubara T, Tsurukai T, Hata K, Nishimura R, Yoneda T. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts. J Bone Miner Res 2008, 23:907-914. 10.1359/jbmr.080211, 18251700.
41. Schett G, David JP. Denosumab--a novel strategy to prevent structural joint damage in patients with RA?. Nat Clin Pract Rheumatol 2008, 4:634-635. 10.1038/ncprheum0927, 18839011.
42. Yasuda Y, Saito M, Yamamura T, Yaguchi T, Nishizaki T. Extracellular adenosine induces apoptosis in Caco-2 human colonic cancer cells by activating caspase-9/-3 via A(2a) adenosine receptors. J Gastroenterol 2009, 44:56-65. 10.1007/s00535-008-2273-7, 19159073.
43. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999, 13:1899-1911. 10.1101/gad.13.15.1899, 10444588.
44. Lee SW, Kim JH, Park YB, Lee SK. Bortezomib attenuates murine collagen-induced arthritis. Ann Rheum Dis 2009, 68:1761-1767. 10.1136/ard.2008.097709, 19054826.
45. Lehman TJ, Schechter SJ, Sundel RP, Oliveira SK, Huttenlocher A, Onel KB. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. J Pediatr 2004, 145:856-857. 10.1016/j.jpeds.2004.08.020, 15580219.
46. Gockel HR, Lugering A, Heidemann J, Schmidt M, Domschke W, Kucharzik T, Lugering N. Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway. J Immunol 2004, 172:5103-5109.
47. Majumdar S, Lamothe B, Aggarwal BB. Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 2002, 168:2644-2651.
48. Grossmann M, Metcalf D, Merryfull J, Beg A, Baltimore D, Gerondakis S. The combined absence of the transcription factors Rel and RelA leads to multiple hemopoietic cell defects. Proc Natl Acad Sci USA 1999, 96:11848-11853. 10.1073/pnas.96.21.11848, 18375, 10518539.